• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

    69.85 -1.24 (-1.74%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 789,065
    Open 70.51
    Bid (Size) 69.84 (100)
    Ask (Size) 69.91 (100)
    Prev. Close 71.09
    Today's Range 67.91 - 70.67
    52wk Range 26.20 - 84.56
    Shares Outstanding 56,367,802
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
    Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    -7.8%
    -7.8%
    1 Month
    +0.3%
    +0.3%
    3 Month
    -9.1%
    -9.1%
    6 Month
    +89.5%
    +89.5%
    1 Year
    +73.1%
    +73.1%

    More News

    Read More
    News headline image
    Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗
    Via Chartmill
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
    Via MarketMinute
    Topics Economy Initial Public Offering
    News headline image
    Apogee Therapeutics to Participate in Upcoming March Conferences
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics to Participate in Upcoming Conferences
    From Apogee Therapeutics
    Via GlobeNewswire
    News headline image
    Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
    From Apogee Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
    Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
    The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
    What is the current price of Apogee Therapeutics, Inc. - Common Stock?
    The current price of Apogee Therapeutics, Inc. - Common Stock is 69.85
    When was Apogee Therapeutics, Inc. - Common Stock last traded?
    The last trade of Apogee Therapeutics, Inc. - Common Stock was at 03/17/26 04:00 PM ET
    What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
    The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 3.94B
    How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
    Apogee Therapeutics, Inc. - Common Stock has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.